Scientists behind the first possible Covid-19 vaccine to clear interim clinical trials say they will reduce the incidence of “extremely confident” Jab disease, possibly by 50%, resulting in a “dramatic” reduction in cases.
The German company Bioentech and the American pharmaceutical firm Pfizer announced worldwide praise last week that their jointly developed vaccine candidate has proven to be 90% effective in preventing people from getting sick.
Urinhin, chief executive of Bioentech, said he hoped further analysis would show that the job was also effective in preventing the spread of the disease – but probably not more than 90%. He added that the impact will not come until next year.
The UK Government’s Joint Committee on Vaccines and Immunizations has released a list of people who have been given priority in receiving the Covid-19 vaccine. The list goes on:
1. All over 80 years of age and health and social worker
2. All 75 years or older.
3. All of those 70 years or older.
4. All ages 65 or older.
5. Adults under the age of 65 are at risk of serious disease and death from Covid-19.
65. Adults under 65 years of age at moderate risk of serious disease and death from Covid-19.
Those. All 60 years of age or older.
All 65 and older.
9. All of these 50 years or older.
10. The rest of the population
Jahin, interviewed by the Guardian earlier this week, told BBC One’s The Andrew Marr Show on Sunday:
“I am very confident that such an effective vaccine will reduce the risk of infection in humans – probably 90% but not 50%. But we must not forget that this can lead to a dramatic reduction in the spread of epidemics.
Hein said that after further analysis of the antibody response of test participants, the effect of the vaccine candidate “within a few months” will have a better idea of the effect of the vaccine candidate “within a few months.”
Bionatech has previously said that a number of important questions about Jab’s effectiveness will only be answered in the coming weeks and months. This is to establish whether the asymptomatic infection can also take a year to stop.
It was not immediately clear how long the vaccine would last after receiving the vaccine, but Zahin said on Sunday that it could take “every year, every second year or every five years” depending on the antibody response.
The companies hope to deliver more than 300 million doses of the vaccine worldwide by April next year, with the first injections taking place the following month. Yahin said it would be too late to make a dramatic impact on the second wave spreading across large parts of Europe and America, but could help cut a “normal winter” in the West next year, Yahin said.
“This winter will be tough. We won’t have a big impact on the number of infections through our vaccines this winter. If all goes well, we will start delivering this year’s vaccine early next year, “he said.
“It simply came to our notice then [not] Will happen until summer. Summer will help us anyway as the rate of infection will decrease. What is absolutely essential is that we get a high vaccination rate until the winter of next year or earlier.
“That means all vaccinations … must be done before next autumn. We’re sure it will happen because several vaccine companies have been asked to increase supplies so we can have a normal winter next year.”
Ahin, whose wife, Izlem Taresi, is Bioentech’s chief medical officer, said she received “extremely comforting” news from Pfizer chief executive Albert Bauer about the outcome of their interim trial at 8am. Asked how he and his wife celebrated the news, Zahin said: “We had tea together… it’s not just British, it’s Turkish.”
Organizer. Zombie aficionado. Wannabe reader. Passionate writer. Twitter lover. Music scholar. Web expert.
